IDEEMATEC
16.3.2021 17:24:07 CET | Business Wire | Press release
Ideematec Inc. , the leading global supplier of solar tracking systems, today announced it was selected by project developer AMDA energía (AMDA) to provide customized solar tracking systems for a 100 megawatt (MW) agro photovoltaics (Agri-PV) project portfolio located in France. The innovative systems will deliver synergistic solutions for the production of organic food crops and clean electricity generation all while providing soil protection and water savings, helping farmers to move towards a low-emissions smart farming labelling.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316005876/en/
The 100 MW portfolio will be composed of multiple 5 MW projects and will meet specific requirements for proper construction on agricultural land in accordance with local regulations.
Ideematec’s engineering team has modified and optimized the Horizon L:TEC tracker model by adjusting the axis heights of the tracker and maximizing the rotation angle for the module to +/- 70 degrees, allowing the trackers to operate synergistically with agricultural equipment. Ideematec also designed an Agri-PV-specific control and agronomic-orientated monitoring system to improve crop production, land quality and address specific needs of each Agri-PV project site.
“Agri-PV projects require flexibility in both the hardware and installation to protect the integrity of the land and ensure that agricultural practices can operate effectively, while harnessing the benefits of clean energy,” said Jorge Gutiérrez Serra, President for AMDA. “We are confident that Ideematec’s durable and customizable solar trackers will fit the needs of an innovative energy system optimized for highly profitable agricultural production for years to come.”
“Our two-in-portrait (2P) module wings, equipped with bifacial modules, allow us to space module rows to support efficient agricultural operations, such as moving large vehicles between module rows, or monitoring sites for agricultural variables to increase generation efficiency,” says Mario Eckl, Co Founder & CEO Ideematec. “These innovations allow our trackers to provide reliable clean energy to projects at scale, without disturbing the local environment or quality of land. The Agri-PV sector is poised for tremendous growth and we are eager to support agricultural-friendly solutions.”
Agricultural-friendly utility-scale solar solutions are growing in popularity in Europe, and Ideematec expects that trend to erupt in both the North American and APAC markets in the coming years, as rural communities find ways to support scaled renewable energy deployment and generate multiple sources of revenue with agricultural lands.
About Ideematec, Inc.
Ideematec, Inc. is a trusted global supplier of solar tracking systems, headquartered in Germany. Established in 2003, the company serves as a pure play tracker provider for the utility-scale sector. Ideematec pioneered the 2P high-span safeTrack Horizon™ tracker, powered by a patented dual drive technology. Since 2017, the company has successfully delivered some of the biggest solar facilities on three continents, including Jordan (250 MW), Australia (350 MW) and Spain (200 MW). For more information please visit: http://www.ideematec.com/
About AMDA energía
AMDA energía is an international global developer focused on the promotion, development and funding of renewable energy generation projects around the world with proven track record in both photovoltaic and wind sectors having developed more than 30 projects in on 3 different continents since it was created in 2008 (Spain, Portugal, France, South Africa, Mozambique, Tunisia, Colombia, Mexico). Thanks to its experienced staff, the core activities cover the complete process of development of a large-scale renewable energy project.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005876/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom